Navigation Links
IIVS Receives First Mark Twain Ethical Science Award for Successes In Replacing Animals for Chemical and Product Safety Testing
Date:6/30/2010

GAITHERSBURG, Md., June 30 /PRNewswire-USNewswire/ -- In recognition of its leadership in the optimization, validation and routine use of non-animal testing methods, The Institute for In Vitro Sciences (IIVS), Inc. has been awarded the first Mark Twain Ethical Science Award. This honor, presented by People for the Ethical Treatment of Animals (PETA), recognizes IIVS for its successes in helping hundreds of companies world-wide utilize testing strategies that minimize the use of animals, while at the same time maintain or improve the current level of safety for the public.

IIVS is a non-profit organization operating as a center of excellence for in vitro (non-animal) methods used for product safety testing purposes. IIVS's knowledge of the science and application of alternatives to animal experiments is recognized by regulatory agencies worldwide. It provides education and training for chemical and personal care product companies internationally, enabling them to successfully apply non-animal methods within their product testing programs. IIVS also performs testing services in their own quality controlled laboratories providing access to their expert scientific team on a contract basis.

"We are honored to be the first recipient of this prestigious award from PETA", said Dr Rodger Curren, President of IIVS. "Their continued support of our work to expand the application of non-animal methods for product testing has been extremely critical for many of our successes". As an example, Curren pointed out that PETA had recently provided partial funding for IIVS to participate in an international study for non-animal methods to detect skin irritants which resulted in the European Union accepting certain reconstructed human skin models for regulatory submissions. Curren added that an increasing number of scientists have found that the use of human artificial tissue constructs for product safety testing can provide much more accurate assessments of the potential risk to humans than testing in animals.

IIVS has worked for over thirteen years to advance the field of in vitro alternatives. The Mark Twain Ethical Science Award provides a clear demonstration of the impact of its work.

About IIVS

IIVS is a non-profit organization wholly dedicated to the promotion of rapid and innovative non-animal testing methods. Founded in 1997, IIVS is recognized as a leading provider of in vitro testing in support of toxicological safety evaluations. Rigorous scientific programs coupled with educational and outreach initiatives have established IIVS as a global leader in the advancement of alternatives to animal testing.

For more information please visit www.iivs.org


'/>"/>
SOURCE Institute for In Vitro Sciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... DUBLIN , Feb. 10, 2016  Allergan plc ... today announced that Brent Saunders , Allergan,s CEO ... in a fireside chat session at the RBC Capital ... 12:30 p.m. ET at The New York Palace Hotel ... presentation will be webcast live and can be accessed ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on ... fill more than 100 tables for its annual event, which will run from ...
(Date:2/10/2016)... CA (PRWEB) , ... February 10, 2016 , ... ... Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads platform, ... 2014. More than 1,600 participants have joined the PROMPT study, which seeks to ...
(Date:2/10/2016)... Jolla CA (PRWEB) , ... February 10, 2016 , ... ... new agents for the treatment of Alzheimer’s disease, announced today it has been selected ... February 18th at the Breakers in Palm Beach, Florida. The purpose of the ...
Breaking Biology Technology:
(Date:1/20/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce the attainment of record-setting corporate ... of the company,s laser focus on (and growing international ... comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... growth achievements in 2015 include: , Record ...
(Date:1/18/2016)... JOSE, Calif. , Jan. 18, 2016 /PRNewswire/ ... security software that simplifies the use and access ... technology and go-to-market partnership with American Cyber.  ... Cyber brings extensive experience leading transformational C4ISR and ... implementing and integrating the latest proven technology solutions," ...
(Date:1/13/2016)... , January 13, 2016 ... published a new market report titled - Biometric Sensors Market ... Forecast, 2015 - 2023. According to the report, the global biometric ... is anticipated to reach US$1,625.8 mn by 2023, expanding ... In terms of volume, the biometric sensors market is ...
Breaking Biology News(10 mins):